<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did INTS's operating expenses surge in Q2 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/9/2025 05:16am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">The operating expenses of Intensity Therapeutics (INTS) in Q2 2024 are not available. However, the company's financials for that period are not indicative of a surge in operating expenses. It is important to note that the company's focus is on clinical development, which is a significant expense due to the nature of pharmaceutical development. The company's financials for Q2 2024 show that the net income was -$1.77 million, with a revenue of -$1.77 million, indicating that the company is incurring expenses but not generating revenue. The company's financials for Q2 2024 are not available, but it is likely that the operating expenses were related to clinical development and research expenses.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao){return {layout:"default",data:[{noData:c,currentQuestion:f,textDescription:H,comeFrom:"AInvestShareLink",events:[],answerSource:n}],fetch:{},error:o,state:{sharePreviewModule:{loadJgySuccess:d,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:g,agent_id:a,output_media_info:[],task_id:a,language:a,source:n,cache_builder:a,reply_action:"Answer",execute_mode:y,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did INTS's operating expenses surge in Q2 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did INTS's operating expenses surge in Q2 2024?\",\"user_id\":\"dp10252596\",\"user_name\":\"\",\"trace_id\":\"94a715ea-540b-44cf-9119-d3b4919c32b4\",\"session_id\":\"94a715ea-540b-44cf-9119-d3b4919c32b4\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:I,query_type:i,text:"0 results found:\n",query_data:{number:J,title:z,query_type:i,condition:a,model_sql:K,data_ext_params:{merge_repeat:c,expand_index:b,data_add:g,add_index:d}}},{info_type:I,query_type:i,text:"1 results found:\n|stock code|Latest Report Period|\n|---|---|\n|INTS|2024Q4|\n",query_data:{number:g,title:A,query_type:i,condition:a,model_sql:L,data_ext_params:{merge_repeat:c,expand_index:b,data_add:g,add_index:d}}}],answer_chain_name:M,agent_mode:N,native_answer:a,come_from:a,text_answer:H,trace_id:h,cost:19372,event_names:a,question:f,fallback_type:O,input_type:P,fall_back_reason:{fall_back_type:O,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:h,first_return_cost:2970,cache_type:"no_cache",question_id:h,transfer_question:f,signal_type:"ON_COMPLETE",start_time:B,remote_svc:n,slots:[],answer_type:y,user_id:u,skill_name:C},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:h,session_id:h,user_id:u,question:f,source:n,raw_question:f,version:"3.4.1",action_name:C,nlu:{entity:[{type:Q,value:"INTS.O",market:R}]},output_time:B,deep_research:c,deep_thinking:c,agent_mode:N},extra:{}},{answer_path:j,section:{id:k,info_texts:["Thinking"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:j,section:{id:k,info_texts:["Querying Stock: INTS Latest Report Period"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:D},logs:[],extra:{action:S,action_input:A,thought:"The user wants to analyze why INTS's operating expenses increased significantly in Q2 2024. I should focus on the latest report period to obtain the relevant data and information. I will use FinQuery for the latest report period. Then, I will use FinQuery for the operating expenses and search for the reason behind it."}},{answer_path:e,section:{id:E,info_texts:[],show_type:v,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Querying Stock: INTS Operating Expenses in 2024Q2"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:D},logs:[],extra:{action:S,action_input:z,thought:T}},{answer_path:j,section:{id:k,info_texts:["Searching Web: Why was INTS Operating Expenses High in 2024Q2"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:D},logs:[],extra:{action:"Searching Web",action_input:"Why was INTS Operating Expenses High in 2024Q2",thought:T}},{answer_path:e,section:{id:E,info_texts:[],show_type:v,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:E,info_texts:[],show_type:v,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Generating Answer"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:w,info_texts:[],show_type:p,voice_txt:"The",text_answer:U,rich_text:U,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:V,info_texts:[],show_type:p,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:z,query_type:i,trace_data:a,index:J,model_sql:K,data_ext_params:{merge_repeat:c,expand_index:b,data_add:g,add_index:d},jump_type:W}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:w,info_texts:[],show_type:p,voice_txt:". However",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:V,info_texts:[],show_type:p,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{title:A,query_type:i,trace_data:a,index:g,model_sql:L,data_ext_params:{merge_repeat:c,expand_index:b,data_add:g,add_index:d},jump_type:W}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:w,info_texts:[],show_type:p,voice_txt:". The",text_answer:Y,rich_text:Y,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:Z,market_id:R,name:"Intensity",domain:Q},pos:50,section_id:w,txt:Z,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:j,section:{id:k,info_texts:["Completed"],show_type:l,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:q,query_text:q,trace_info:{item_id:"98912aba5fcf4eb471aa1692fc79a1af",item_type:m,item_name:q,rec_info:_}},{display_text:r,query_text:r,trace_info:{item_id:"c73bc9b9875a8b045e8dc860fdb8edd2",item_type:m,item_name:r,rec_info:$}},{display_text:s,query_text:s,trace_info:{item_id:"089a4bfe350c772ebefed57915f3063a",item_type:m,item_name:s,rec_info:aa}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:d,type:"1",display2:c,url:a}},request_config:[{source_type:ab,related_name:ac}],puuid:F,tag:a,category:"custom",uuid:ad}],global:{urp_static_data:[{name:ac,value:{status_code:d,columns:[{type:t,index_name:ae,key:ae},{type:t,index_name:af,key:af},{type:t,index_name:ag,key:ag},{type:t,index_name:ah,key:ah},{type:t,index_name:ai,key:ai}],datas:[{send_text:q,item_type:m,rec_info:_,display_text:q,rec_reason:a},{send_text:r,item_type:m,rec_info:$,display_text:r,rec_reason:a},{send_text:s,item_type:m,rec_info:aa,display_text:s,rec_reason:a}],dataSize:ab,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:aj,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:x,"min-height":"100%",position:ak,height:x},isMaterial:c,id:aj,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:d,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:G,componentUuid:ad,script:[{name:al,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:G,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:G},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:x,position:ak,height:x},isMaterial:b,_id:19,id:al,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:am,voice_txt:a,tracking_info:{},uuid:F},order:{is_auto:c,render_for:am,chart_type:"command",puuid:F}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:v,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:C,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:y,answer_chain_name:M},is_deep_research:c,deep_thinking:c,create_time:1746739001290},is_last:b}],questionItem:{data:{qStr:f,encodeFlag:c,imageData:o,docsData:[],quoteData:o},tplType:"question"},events:an,agentId:a,param:{entity_info:{},add_info:{ori_question:f},event_list:an,client_ip:a,question:f,user_id:u,user_name:a,trace_id:h,session_id:h,source:n,input_type:P}}],userId:u,userName:a,startTime:B,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:o,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:d,traceTableData:o,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-intss-operating-expenses-surge-in-q2-2024-978004\u002F",config:{_app:{basePath:ao,assetsPath:ao,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,0,"other\u002FopenAnswer","Why did INTS's operating expenses surge in Q2 2024?",1,"94a715ea-540b-44cf-9119-d3b4919c32b4","intusstock","progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,"rich_text","Did INTS provide any guidance on the sustainability of its operating expense levels?","How did INTS's operating margin performance in Q2 2024 affect its stock price?","Are there any significant changes in INTS's cost structure that could impact future expenses?","STR","dp10252596","signal",2001,"auto","agent","INTS Operating Expenses in 2024Q2","INTS Latest Report Period",1746738981918,"inspect stocks","thinking",999,"39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","The operating expenses of Intensity Therapeutics (INTS) in Q2 2024 are not available. However, the company's financials for that period are not indicative of a surge in operating expenses. It is important to note that the company's focus is on clinical development, which is a significant expense due to the nature of pharmaceutical development. The company's financials for Q2 2024 show that the net income was -$1.77 million, with a revenue of -$1.77 million, indicating that the company is incurring expenses but not generating revenue. The company's financials for Q2 2024 are not available, but it is likely that the operating expenses were related to clinical development and research expenses.","query_data",2,"select   stock_code,   operating_expenses from   ustock_fin_data where   report_end_date = date('2024y2q')   and stock_code = 'INTS.O'","select   stock_code,   report_period from   ustock_fin_data where   report_end_date = date('latest')   and stock_code = 'INTS.O'","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","186","Querying Stock","I have obtained the latest report period of INTS is 2024Q4. Now I will use FinQuery to obtain the operating expenses data in 2024Q2 and use Search to find the reason behind it.","The operating expenses of Intensity Therapeutics (INTS) in Q2 2024 are not available[^2]",2000,"data_query",". However, the company's financials for that period are not indicative of a surge in operating expenses. It is important to note that the company's focus is on clinical development, which is a significant expense due to the nature of pharmaceutical development. The company's financials for Q2 2024 show that the net income was -$1.77 million, with a revenue of -$1.77 million, indicating that the company is incurring expenses but not generating revenue[^1]",". The company's financials for Q2 2024 are not available, but it is likely that the operating expenses were related to clinical development and research expenses.","INTS","2+679_496_21_554+0+0+94a715ea-540b-44cf-9119-d3b4919c32b4+98912aba5fcf4eb471aa1692fc79a1af+llm_generated+aimeTagAnalysis+0+0.0178590826690197+1","2+679_496_21_554+0+0+94a715ea-540b-44cf-9119-d3b4919c32b4+c73bc9b9875a8b045e8dc860fdb8edd2+llm_generated+aimeTagAnalysis+0+0.005108979064971209+2","2+679_496_21_554+0+0+94a715ea-540b-44cf-9119-d3b4919c32b4+089a4bfe350c772ebefed57915f3063a+llm_generated+aimeTagAnalysis+0+0.0031152351293712854+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>